The government is paying close attention to the correction plan for the price volume agreement (PVA) system that will be applied to respiratory drugs such as cold medicines whose usage has increased due to COVID-19.

Therefore, the schedule the authorities had set to start PVA monitoring in April after finalizing the correction plan within the month is expected to be somewhat delayed. The health insurance authorities plan to make a final decision after calculating the number of products subject to PVA through simulation when it applies the correction plan.

According to industry sources on the 30th, the National Health Insurance Service collected the opinion of the pharmaceutical industry